Navigation Links
Martek Announces First Quarter 2009 Financial Results
Date:3/4/2009

-6; and granulocyte monocyte-colony stimulating factor. There was a corresponding increase in the concentration of anti-inflammatory matrix metalloproteinase. The authors noted that the reduction of CRP was similar to that seen with statins. Overall, the authors concluded that supplemental DHA may lessen the inflammatory response. Martek's life'sDHA(TM) was used in this study.

Financial Guidance

Martek expects total revenues for the second quarter of fiscal 2009 to be between $87 million and $92 million with second quarter infant formula revenue projected to be between $76 million and $80 million and second quarter non-infant formula nutritional revenue projected to be between $7 million and $9 million. Second quarter gross margin is expected to be approximately 42.5%. Net income for the second quarter is projected to be between $8.9 million and $10.3 million, and diluted earnings per share are projected to be between $0.27 and $0.31.

For the full fiscal year 2009, consistent with previous guidance, the Company continues to expect moderate growth of both revenues and profitability over fiscal 2008 with profitability continuing to grow at a higher rate than revenues primarily due to improvements in gross profit margins. However, if the current worldwide economic recession remains deep and prolonged, there is greater uncertainty with respect to the Company's ability to attain its forecasted operating results.

Investor Conference Call Webcast

Martek will host a conference call and Webcast for investors to review its first quarter results and fiscal 2009 outlook at 4:45 p.m. Eastern Time on Wednesday, March 4, 2009. Access to the live audio Webcast is available through Martek's website at http://investors.martek.com. The webcast will be available
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Martek, General Mills Collaborate on Microencapsulation Technology for Food Applications
2. Martek to Present at 11th Annual ICR XChange
3. Martek to Present at Upcoming Needham Conference
4. Martek Announces Fourth Quarter and FY 2008 Financial Results
5. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
6. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
7. Martek to Present at Upcoming Canaccord Adams Conference
8. Martek to be the Sole Source Supplier of DHA and ARA for Infant Formulas Produced By Grupo Ricap
9. Martek is Now the Sole-Source Supplier of ARA for all Infant Formula Products Manufactured by Hochdorf Nutricare
10. Martek Signs Multi-Year Sole-Source Supply Agreement With Hero
11. Martek Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Belmont, Mass. (PRWEB) August 27, 2014 ... of top technology vendors,” said Ven Thangaraj, CEO of ... imaging solutions that are taking the imaging corelab market ... trial sponsors, corelabs and research organizations to efficiently and ... and prepare the data to be analyzed and read ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... The Graphene Opportunity - A Rational View ... Graphene The New Nanotech? A similar amount ... of applications ranging from microelectronics to water treatment, ... announced the availability of the Graphene Opportunity Report, ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
Breaking Biology Technology:Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... to Initiate Phase II Trial for IPLEX(TM) in ... Sweden, Sept. 23 ,Insmed Inc. (Nasdaq CM: INSM), ... Premacure AB, a biopharmaceutical company,dedicated to the development ... to premature birth, today noted the presentation of,clinical ...
... REDWOOD CITY, Calif., Sept. 23 Codexis, Inc., ... Vice President,Intellectual Property. She will be responsible for ... portfolio and will,report to Douglas Sheehy, Vice President, ... Codexis from Danisco A/S, where as Senior,Director, Intellectual ...
... 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) today ... with Toray,Industries Inc. of Japan to obtain the ... Toraymyxin(TM), a therapeutic for the treatment of,sepsis that ... of the,agreement, the Company will seek FDA approval ...
Cached Biology Technology:Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 2Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 3Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 4Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 5Codexis Names Vice President, Intellectual Property 2Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3
(Date:8/28/2014)... A new study reports that an expansion of marine ... perform key ecological functions. According to investigators from ... at protecting fish have focused on saving the largest ... species that provide key and difficult-to-replace ecological functions. ... are performed by fish species that also are food ...
(Date:8/28/2014)... Clinic researcher and his collaborators have developed an online ... process of re-engineering cells for biomedical investigation. CellNet is ... to aid stem cell engineering. Details of CellNet and ... two back-to-back papers in the journal Cell . ... uses for all types of cell-based investigations and can ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... in their fight against a dangerous bacterium that sickens ... such as catheters, artificial joints and heart valves. , ... has, for the first time, been shown to protect ... would otherwise kill the bacteria, according to scientists at ...
... access publishing and the NIH new policy from ... of Health (NIH) rule on Enhanced Public Access to ... and a missed opportunity to take advantage of available ... the nation's leading not-for-profit medical and scientific publishers. The ...
... follow up of the NIH public access policy announced ... Central : , BioMed Central welcomes the announcement ... access policy. The NIH calls on all of its grantees ... National Library of Medicine's PubMed Central and make them freely ...
Cached Biology News:Substance protects resilient staph bacteria 2Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3BioMed Central welcomes the new National Institutes of Health public access policy 2
... The ScriptCap™ 2'-O-Methyltransferase converts Cap 0 ... mRNA. The Cap 1 structure has been ... by up to 50%. This improvement is ... the ScriptCap™ m7G Capping System as well ...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Biology Products: